Log In
Print
BCIQ
Print
Print this Print this
 

Anti-KIR3DL2 mAb (IPH41)

  Manage Alerts
Collapse Summary General Information
Company Innate Pharma S.A.
DescriptionAnti-killer cell immunoglobulin-like receptor three domains long cytoplasmic tail 2 (KIR3DL2; CD158K) mAb
Molecular Target Killer cell immunoglobulin-like receptor three domains long cytoplasmic tail 2 (KIR3DL2) (CD158K)
Mechanism of Action 
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationLeukemia
Indication DetailsTreat T cell leukemia/lymphoma
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today